TheStreet’s Action Alerts PLUS Portfolio Manager Jim Cramer said Allergan is eviscerating Valeant Pharmaceuticals’ business. ‘Allergan has an unbelievable dermatological franchise,’ Cramer said, adding that it’s difficult for Valeant to compete. On Tuesday, Valeant reported lower full-year guidance and expects earnings of $6.60 to $7.00 a share, compared to a previously reported range of $8.50 to $9.50 a share. The company posted first quarter earnings of $1.27 a share, missing estimates of $1.37 a share. Valeant’s share have lost 76 percent of their value since the start of 2016.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
